- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06110494
A New Clinical Use of Ferumoxytol Nanoparticles: An Antibiofilm Treatment
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- University of Pennsylvania
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patients to welling to participate in the study.
- Patients are 18 years or above.
- Non-contributory medical history (Patient can be seen for regular dental appointment in PDM; ASA classes I and II).
- Tooth requiring root canal treatment with radiographic presence of periapical radiolucency and responding to thermal sensitivity testing negatively (difluordichlormethane at 50 °C) (Endo-Ice, Coltène/Whaledent Inc., Cuyahoga Falls, Ohio) and Negatively to EPT testing.
- Tooth with adequate remaining tooth structure for proper isolation with rubber dam.
- No history of previous endodontic treatment on the tooth.
- Teeth with single canal and single and roots with single canals in multirooted teeth.
Exclusion Criteria:
- Self-reported Pregnancy.
- Patients requiring antibiotic premedication prior to dental treatment.
- Patients with multiple drug allergies.
- Patients with known hypersensitivity to Ferumoxytol nanoparticles or any iron products.
- Patients who are scheduled for MRI for the head region within three months after Fer nanoparticles application.
- Periodontal changes (pockets 3 mm, mobility Grade I or gingival edema).
- Radiographic presence of resorptive processes.
- Cracked and fractured teeth.
- if one of the inclusion criteria is not met
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Iron oxide nanoparticles treatment Ferumoxytol/H2O2
After access preparation with sterile burs and sterile saline irrigation and working length determination as part of routine root canal treatment, and after obtaining a pre-treatment bacteriological samples, 2 mL of a mixture of Ferumoxytol (6mg/mL)/H2O2(3%) was introduced into the canal.
Canals were instrumented with 15/0.04,
20/0.04, and 25/0.04 rotary files using 2 mL of treatment solution after each file with a total of 8 mL of solution used and a total contact time of 10 minutes.
|
Participants receive a topical treatment through a root canal irrigation needle containing A mixture of 6mg/mL Ferumoxytol nanoparticles solution mixed with 3% H2O2 for 10 minutes contact time
Other Names:
All canals in all groups were irrigated with 2 mL of 3% NaOCl, followed by ultrasonic irrigant activation for 30s twice. seconds. This step was repeated once again making the total activation time 1 min and the total contact time of the irrigant 3 min. Upon completion of irrigation, a third bacterial sample (S3) was taken following the deactivation, washing, drying, and sampling steps as described previously
Other Names:
|
|
Active Comparator: Sodium Hypochlorite (NaOCl)
After access preparation with sterile burs and sterile saline irrigation and working length determination as part of routine root canal treatment, and after obtaining a pre-treatment bacteriological samples, 2 mL of 3% NaOCl was introduced into the canal.
Canals were instrumented with 15/0.04,
20/0.04, and 25/0.04 rotary files using 2 mL of solution after each file with a total of 8 mL of treatment solution used and a total contact time of 10 minutes.
|
Participants receive a topical treatment through a root canal irrigation needle containing 3% NaOCl for 10 minutes contact time
Other Names:
All canals in all groups were irrigated with 2 mL of 3% NaOCl, followed by ultrasonic irrigant activation for 30s twice. seconds. This step was repeated once again making the total activation time 1 min and the total contact time of the irrigant 3 min. Upon completion of irrigation, a third bacterial sample (S3) was taken following the deactivation, washing, drying, and sampling steps as described previously
Other Names:
|
|
Placebo Comparator: Saline (NaCl)
After access preparation with sterile burs and sterile saline irrigation and working length determination as part of routine root canal treatment, and after obtaining a pre-treatment bacteriological samples, 2 mL of 0.89% NaCl was introduced into the canal.
Canals were instrumented with 15/0.04,
20/0.04, and 25/0.04 rotary files using 2 mL of treatment solution after each file with a total of 8 mL of solution used and a total contact time of 10 minutes.
|
Participants receive a topical treatment through a root canal irrigation needle containing 0.89% NaCl for 10 minutes contact time
Other Names:
All canals in all groups were irrigated with 2 mL of 3% NaOCl, followed by ultrasonic irrigant activation for 30s twice. seconds. This step was repeated once again making the total activation time 1 min and the total contact time of the irrigant 3 min. Upon completion of irrigation, a third bacterial sample (S3) was taken following the deactivation, washing, drying, and sampling steps as described previously
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
The Primary Outcome Parameter Will be the Difference in Bacterial Reduction Between the Experimental and Control Disinfection Groups Group (Ferumoxytol) and Comparison Groups (Positive and Negative Controls).
Time Frame: baseline (pretreatment) and after 10 minutes of treatment (post treatment)
|
This study is designed to evaluate the antibacterial efficacy of Ferumoxytol/H2O2 and to compare it to the gold standard disinfection solution (NaOCl) and negative control solution (NaCl).
The outcome will be evaluated by taking bacterial samples from the root canals during routine root canal treatment before and after applying different disinfection protocols.
The disinfection efficacy was calculated by comparing the difference in microbial CFU reduction (post treatment sample/pretreatment sample) between the three disinfection protocols
|
baseline (pretreatment) and after 10 minutes of treatment (post treatment)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
The Effect of Additional (Supplementary) Irrigation and Adjunctive Irrigant (NaOCl) Activation Using Passive Ultrasonic Activation After Irrigation With Experimental and Control Irrigants.
Time Frame: the baseline of this measurement starts right after treatment with either experimental, negative or positive control agent (S2). This measurement ends after irrigating the canals with NaOCl and irritant activation for 3 minutes.
|
All groups received an additional irrigation step with NaOCl with passive ultrasonic activation.
An additional step was included for all the test groups to evaluate if further irrigation after (S2) will lead to more reduction of bacterial counts inside the root canal system.
This could inform future experiments evaluating the possibility of synergistic antimicrobial effects for the sequential ferumoxytol and NaOCl treatment.
|
the baseline of this measurement starts right after treatment with either experimental, negative or positive control agent (S2). This measurement ends after irrigating the canals with NaOCl and irritant activation for 3 minutes.
|
|
The Overall Effect of Antimicrobial Irrigation of Infected Root Canals Using Experimental and Control Irrigants, in Addition to Supplementary Irrigant (NaOCl) Activation.
Time Frame: This measure starts at baseline (pretreatment) (S1). This measure ends after 10 minutes of treatment with either experimental, positive or negative control irrigants and additional 3 minutes of supplementary irrigation (S3)
|
All groups received treated with either Experimental (ferumoxytol), NaOCl (positive control) or Saline (NaCl, negative control).
Followed by supplementary irrigation and activation.
This could inform future experiments evaluating the possibility of synergistic antimicrobial effects for the sequential ferumoxytol and NaOCl treatment.
|
This measure starts at baseline (pretreatment) (S1). This measure ends after 10 minutes of treatment with either experimental, positive or negative control irrigants and additional 3 minutes of supplementary irrigation (S3)
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Bekir Karabucak, DMD, MS, University of Pennsylvania
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Periodontal Diseases
- Mouth Diseases
- Tooth Diseases
- Jaw Diseases
- Periapical Diseases
- Periodontitis
- Periapical Periodontitis
- Dental Pulp Diseases
- Stomatognathic Diseases
- Anti-Infective Agents
- Hematinics
- Pharmaceutical Solutions
- Parenteral Nutrition Solutions
- Disinfectants
- Ferrosoferric Oxide
- Sodium Hypochlorite
- Eusol
Other Study ID Numbers
- 828211
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ICF
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Apical Periodontitis
-
RANA AHMADNot yet recruitingSymptomatic Apical Periodontitis | Irreversible Pulpitis With Apical Periodontitis
-
Marmara UniversityMarmara University Scientific Research Projects UnitCompletedChronic Apical PeriodontitisTurkey (Türkiye)
-
Mustafa Kemal UniversityActive, not recruitingChronic Apical PeriodontitisTurkey (Türkiye)
-
The Dental Hospital of Zhejiang University School...RecruitingChronic Apical PeriodontitisChina
-
Ataturk UniversityActive, not recruiting
-
Fatima Memorial HospitalRecruitingAsymptomatic Apical PeriodontitisPakistan
-
Suez Canal UniversityUniversity of LeedsActive, not recruitingAsymptomatic Apical PeriodontitisEgypt
-
Aga Khan UniversityCompletedChronic Apical PeriodontitisPakistan
-
Nanfang Hospital, Southern Medical UniversityRecruitingChronic Apical PeriodontitisChina
-
bengi gülgüRecruitingOxidative Stress | Chronic Apical PeriodontitisTurkey
Clinical Trials on Iron oxide nanoparticles treatment Ferumoxytol/H2O2
-
The First Affiliated Hospital with Nanjing Medical...Chia Tai Tianqing Pharmaceutical Group Co., Ltd.RecruitingCoronary Artery CalcificationChina
-
University of PennsylvaniaNot yet recruitingApical Periodontitis | Endodontic Disease | Root Canal InfectionUnited States
-
The First Affiliated Hospital with Nanjing Medical...Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Recruiting
-
Massachusetts General HospitalCompletedPapillary Carcinoma of Thyroid Gland | Metastatic Medullary Thyroid Cancer | Follicular Thyroid Cancer Lymph Node MetastasisUnited States
-
Min ZhouRecruitingVenous DiseasesChina
-
University of AlbertaCanadian Institutes of Health Research (CIHR)RecruitingEpilepsy, Temporal LobeCanada
-
The First Affiliated Hospital with Nanjing Medical...Chia Tai Tianqing Pharmaceutical Group Co., Ltd.CompletedChronic Kidney DiseasesChina
-
AMAG Pharmaceuticals, Inc.CompletedAnemia | Iron Deficiency | Kidney DiseaseUnited States, Belgium, Canada, Germany, India, Poland, United Kingdom
-
AMAG Pharmaceuticals, Inc.CompletedIron Deficiency Anemia Treatment | Chronic Kidney Disease(CKD)United States, Canada, United Kingdom
-
AMAG Pharmaceuticals, Inc.CompletedAnemiaUnited States